Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;45(7):742-751.
doi: 10.1002/clc.23831. Epub 2022 Apr 14.

Distinguishing exercise intolerance in early-stage pulmonary hypertension with invasive exercise hemodynamics: Rest VE /VCO2 and ETCO2 identify pulmonary vascular disease

Affiliations

Distinguishing exercise intolerance in early-stage pulmonary hypertension with invasive exercise hemodynamics: Rest VE /VCO2 and ETCO2 identify pulmonary vascular disease

Farhan Raza et al. Clin Cardiol. 2022 Jul.

Abstract

Background: Among subjects with exercise intolerance and suspected early-stage pulmonary hypertension (PH), early identification of pulmonary vascular disease (PVD) with noninvasive methods is essential for prompt PH management.

Hypothesis: Rest gas exchange parameters (minute ventilation to carbon dioxide production ratio: VE /VCO2 and end-tidal carbon dioxide: ETCO2 ) can identify PVD in early-stage PH.

Methods: We conducted a retrospective review of 55 subjects with early-stage PH (per echocardiogram), undergoing invasive exercise hemodynamics with cardiopulmonary exercise test to distinguish exercise intolerance mechanisms. Based on the rest and exercise hemodynamics, three distinct phenotypes were defined: (1) PVD, (2) pulmonary venous hypertension, and (3) noncardiac dyspnea (no rest or exercise PH). For all tests, *p < .05 was considered statistically significant.

Results: The mean age was 63.3 ± 13.4 years (53% female). In the overall cohort, higher rest VE /VCO2 and lower rest ETCO2 (mm Hg) correlated with high rest and exercise pulmonary vascular resistance (PVR) (r ~ 0.5-0.6*). On receiver-operating characteristic analysis to predict PVD (vs. non-PVD) subjects with noninvasive metrics, area under the curve for pulmonary artery systolic pressure (echocardiogram) = 0.53, rest VE /VCO2 = 0.70* and ETCO2 = 0.73*. Based on this, optimal thresholds of rest VE /VCO2 > 40 mm Hg and rest ETCO2 < 30 mm Hg were applied to the overall cohort. Subjects with both abnormal gas exchange parameters (n = 12, vs. both normal parameters, n = 19) had an exercise PVR 5.2 ± 2.6* (vs. 1.9 ± 1.2), mPAP/CO slope with exercise 10.2 ± 6.0* (vs. 2.9 ± 2.0), and none included subjects from the noncardiac dyspnea group.

Conclusions: In a broad cohort of subjects with suspected early-stage PH, referred for invasive exercise testing to distinguish mechanisms of exercise intolerance, rest gas exchange parameters (VE /VCO2 > 40 mm Hg and ETCO2 < 30 mm Hg) identify PVD.

Keywords: ETCO2; VE/VCO2; cardiopulmonary exercise test; invasive exercise hemodynamics; pulmonary hypertension; pulmonary vascular disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Representative figure of invasive exercise hemodynamics with cardiopulmonary exercise testing. CPET, cardiopulmonary exercise test.
Figure 2
Figure 2
Correlation of rest ETCO2 (A&B) and V E/VCO2 (C&D) with rest and exercise PVR. ETCO2, end‐tidal carbon dioxide pressure; PVR, pulmonary vascular resistance; V E/VCO2, minute ventilation to carbon dioxide production ratio.
Figure 3
Figure 3
Distribution of rest gas exchange parameters among the overall cohort and hemodynamic profile. Abnormal thresholds for rest ETCO2 (<30 mm Hg) and V E/VCO2 (>40 mm Hg) Both normal: green (n = 26), one abnormal: blue (n = 17), both abnormal: red (n = 12). ANOVA p < .001 for all three analyses. For pairwise comparisons, both normal (green) = a, one abnormal (blue) = b, and both abnormal (red) = c. ANOVA, analysis of variance; CO, cardiac output; ETCO2, end‐tidal carbon dioxide pressure; mPAP, mean pulmonary artery pressure; PET, cardiopulmonary exercise test; PVR, pulmonary vascular resistance; V E/VCO2, minute ventilation to carbon dioxide production ratio.

References

    1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1).​ 10.1183/13993003.01913-2018 - DOI - PMC - PubMed
    1. Raza F, Alkhouli M, Rogers F, Vaidya A, Forfia P. Case series of 5 patients with end‐stage renal disease with reversible dyspnea, heart failure, and pulmonary hypertension related to arteriovenous dialysis access. Pulm Circ. 2015;5(2):398‐406. 10.1086/681266 - DOI - PMC - PubMed
    1. Lacharite‐Roberge AS, Raza F, Bashir R, et al. Case series of seven women with uterine fibroids associated with venous thromboembolism and chronic thromboembolic disease. Pulm Circ. 2019;9(1):2045894018803873. 10.1177/2045894018803873 - DOI - PMC - PubMed
    1. Raza F, Vaidya A, Lacharite‐Roberge AS, et al. Initial clinical and hemodynamic results of a regional pulmonary thromboendarterectomy program. J Cardiovasc Surg. 2018;59(3):428‐437. 10.23736/S0021-9509.17.10188-6 - DOI - PubMed
    1. Raza F, Kozitza C, Chybowski A, et al. Interferon‐β‐induced pulmonary arterial hypertension: approach to diagnosis and clinical monitoring. JACC Case Rep. 2021;3:1‐6. 10.1016/j.jaccas.2021.02.005 - DOI - PMC - PubMed